Moderna's Cancer Vaccine Shows Promising Phase 3 Results

Moderna's COVID-19 vaccine has been a historic success, contributing to a 460% stock surge over the past 12 months. The company's approval for its influenza vaccine, mFLUSIVA, is expected to contribute meaningfully to its financial results. However, the recent phase 3 clinical trial success of its investigational personalized cancer vaccine, intismeran autogene, has sent the stock soaring. This achievement demonstrates the potential of Moderna's mRNA technology beyond infectious diseases and into oncology.